However, in Japanese population, serum fetuin A level is found to be negatively associated with liver/vessel fibrosis-related markers in NAFLD patients, indicating that circulating Fetuin A could be a useful serum biomarker for predicting liver and vascular fibrosis progression in NAFLD patients [18]. This evidence concerns the gene AHSG and metabolic dysfunction-associated steatotic liver disease.